6 Aug 2025 (In 4 days) Date | | 0.5 Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
27 Aug 2024 Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 4 days) Date | | 0.5 Cons. EPS | - EPS |
5 Nov 2024 Date | | - Cons. EPS | - EPS |
27 Aug 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers—Specialty & Generic Industry | Healthcare Sector | Mr. Blaise A. Coleman CEO | OTC PINK Exchange | - ISIN |
United States Country | 2,931 Employees | - Last Dividend | - Last Split | - IPO Date |
Endo Inc. is a specialty pharmaceutical company with a global reach, dedicated to developing, manufacturing, marketing, and selling a wide array of pharmaceutical products. Established in 1997 and based in Malvern, Pennsylvania, Endo operates across four main segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company focuses on providing high-quality products for the treatment of various conditions across urology, orthopedics, endocrinology, and other fields. Endo's approach combines expertise in specialty pharmaceuticals with a commitment to innovation and patient care, serving diverse markets in the United States and internationally.
Endo's Branded Pharmaceuticals segment offers innovative treatments for conditions in urology, orthopedics, and endocrinology. Notable products include XIAFLEX, a non-surgical treatment for adult men with Peyronie's Disease or Dupuytren's Contracture, offering relief in cases of abnormal collagen buildup. This segment is fervent in pursuing additional indications for XIAFLEX, including treatments for plantar fibromatosis and plantar fasciitis, as well as initiating pre-clinical developments for conditions such as arthrofibrosis of the knee.
This segment provides essential emergency and therapeutic treatments through products like ADRENALIN, for the emergency treatment of allergic reactions including anaphylaxis, and VASOSTRICT, which is used to increase blood pressure in adults experiencing vasodilatory shock who do not respond adequately to fluids and catecholamines.
Endo offers a broad portfolio of generic pharmaceuticals that include solid oral extended-release, solid oral immediate release, liquids, semi-solids, patches, powders, ophthalmics, and sprays. These products cater to a wide range of medical conditions, ensuring accessibility and affordability in healthcare treatment options.
Through its International Pharmaceuticals segment, Endo brings a variety of specialty pharmaceutical products primarily to the Canadian market. These products cover therapeutic areas such as attention deficit hyperactivity disorder (ADHD), pain, women's health, oncology, transplantation, and include over-the-counter products, addressing a comprehensive range of healthcare needs.